{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:52:08Z","timestamp":1791550328798,"version":"4.3.4"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Bioeng"],"DOI":"10.1038\/s44222-026-00487-7","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:02:39Z","timestamp":1789016559000},"page":"970-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-enabled clinical trials"],"prefix":"10.1038","volume":"4","author":[{"given":"Marc","family":"Raynaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Trayanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-3680","authenticated-orcid":false,"given":"Roslyn B.","family":"Mannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Murali","family":"Doraiswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-7747","authenticated-orcid":false,"given":"Alexandre","family":"Loupy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"487_CR1","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMms1604593","volume":"374","author":"LE Bothwell","year":"2016","unstructured":"Bothwell, L. E., Greene, J. A., Podolsky, S. H. & Jones, D. S. Assessing the gold standard \u2014 lessons from the history of RCTs. N. Engl. J. Med. 374, 2175\u20132181 (2016).","journal-title":"N. Engl. J. Med."},{"key":"487_CR2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"487_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ejhf.3218","volume":"26","author":"J Tromp","year":"2024","unstructured":"Tromp, J. et al. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction \u2014 results from the EMPULSE trial. Eur. J. Heart Fail. 26, 963\u2013970 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"487_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"487_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711\u20131723 (2020).","journal-title":"N. Engl. J. Med."},{"key":"487_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"487_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"487_CR8","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"487_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000326","volume":"7","author":"H Bastian","year":"2010","unstructured":"Bastian, H., Glasziou, P. & Chalmers, I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 7, e1000326 (2010).","journal-title":"PLoS Med."},{"key":"487_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrd.2017.70","volume":"16","author":"L Martin","year":"2017","unstructured":"Martin, L., Hutchens, M., Hawkins, C. & Radnov, A. How much do clinical trials cost? Nat. Rev. Drug Discov. 16, 381\u2013382 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"487_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell, P. M. External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d\u00a0Lancet 365, 82\u201393 (2005).","journal-title":"Lancet"},{"key":"487_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","volume":"297","author":"HG Van Spall","year":"2007","unstructured":"Van Spall, H. G., Toren, A., Kiss, A. & Fowler, R. A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. J. Am. Med. Assoc. 297, 1233\u20131240 (2007).","journal-title":"J. Am. Med. Assoc."},{"key":"487_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/cc9021","volume":"14","author":"B Roozenbeek","year":"2010","unstructured":"Roozenbeek, B., Lingsma, H. F., Steyerberg, E. W. & Maas, A. I. Underpowered trials in critical care medicine: how to deal with them? Crit. Care 14, 423 (2010).","journal-title":"Crit. Care"},{"key":"487_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1164\/rccm.201401-0056CP","volume":"189","author":"MO Harhay","year":"2014","unstructured":"Harhay, M. O. et al. Outcomes and statistical power in adult critical care randomized trials. Am. J. Respir. Crit. Care Med. 189, 1469\u20131478 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"487_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7010","volume":"7","author":"M Egger","year":"2003","unstructured":"Egger, M., Juni, P., Bartlett, C., Holenstein, F. & Sterne, J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol. Assess. 7, 1\u201376 (2003).","journal-title":"Health Technol. Assess."},{"key":"487_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMra1601511","volume":"375","author":"SJ Pocock","year":"2016","unstructured":"Pocock, S. J. & Stone, G. W. The primary outcome is positive \u2014 is that good enough? N. Engl. J. Med. 375, 971\u2013979 (2016).","journal-title":"N. Engl. J. Med."},{"key":"487_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.117.003753","author":"NS Tan","year":"2017","unstructured":"Tan, N. S. et al. Temporal trends in use of composite end points in major cardiovascular randomized clinical trials in prominent medical journals. Circ. Cardiovasc. Qual. Outcomes https:\/\/doi.org\/10.1161\/circoutcomes.117.003753 (2017).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"487_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","volume":"179","author":"B Gyawali","year":"2019","unstructured":"Gyawali, B., Hey, S. P. & Kesselheim, A. S. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern. Med. 179, 906\u2013913 (2019).","journal-title":"JAMA Intern. Med."},{"key":"487_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1681\/ASN.2014040378","volume":"26","author":"MD Stegall","year":"2015","unstructured":"Stegall, M. D., Gaston, R. S., Cosio, F. G. & Matas, A. Through a glass darkly: seeking clarity in preventing late kidney transplant failure. J. Am. Soc. Nephrol. 26, 20\u201329 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"487_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.4093\/dmj.2020.0257","volume":"44","author":"JH Yoo","year":"2020","unstructured":"Yoo, J. H. & Kim, J. H. Time in range from continuous glucose monitoring: a novel metric for glycemic control. Diabetes Metab. J. 44, 828\u2013839 (2020).","journal-title":"Diabetes Metab. J."},{"key":"487_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/HYPERTENSIONAHA.121.18413","volume":"79","author":"M Brunstr\u00f6m","year":"2022","unstructured":"Brunstr\u00f6m, M., Thomopoulos, C., Carlberg, B., Kreutz, R. & Mancia, G. Methodological aspects of meta-analyses assessing the effect of blood pressure-lowering treatment on clinical outcomes. Hypertension 79, 491\u2013504 (2022).","journal-title":"Hypertension"},{"key":"487_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04057-z","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink, H. J. L. et al. A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04057-z (2025).","journal-title":"Nat. Med."},{"key":"487_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.qai.0000247227.22504.ce","volume":"44","author":"D Follmann","year":"2007","unstructured":"Follmann, D. et al. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J. Acquir. Immune Defic. Syndr. 44, 49\u201360 (2007).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"487_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1 \u2014 standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur. J. Cancer 62, 138\u2013145 (2016).","journal-title":"Eur. J. Cancer"},{"key":"487_CR25","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/eurheartj\/ehv164","volume":"36","author":"WS Weintraub","year":"2015","unstructured":"Weintraub, W. S., L\u00fcscher, T. F. & Pocock, S. The perils of surrogate endpoints. Eur. Heart J. 36, 2212\u20132218 (2015).","journal-title":"Eur. Heart J."},{"key":"487_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1681\/ASN.0000000000000260","volume":"35","author":"M Raynaud","year":"2024","unstructured":"Raynaud, M. et al. Prognostic biomarkers in kidney transplantation: a systematic review and critical appraisal. J. Am. Soc. Nephrol. 35, 177\u2013188 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"487_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","volume":"8","author":"RL Prentice","year":"1989","unstructured":"Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8, 431\u2013440 (1989).","journal-title":"Stat. Med."},{"key":"487_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","volume":"125","author":"TR Fleming","year":"1996","unstructured":"Fleming, T. R. & DeMets, D. L. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125, 605\u2013613 (1996).","journal-title":"Ann. Intern. Med."},{"key":"487_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrclinonc.2010.43","volume":"7","author":"M Buyse","year":"2010","unstructured":"Buyse, M., Sargent, D. J., Grothey, A., Matheson, A. & de Gramont, A. Biomarkers and surrogate end points \u2014 the challenge of statistical validation. Nat. Rev. Clin. Oncol. 7, 309\u2013317 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"487_CR30","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/sim.5403","volume":"31","author":"TR Fleming","year":"2012","unstructured":"Fleming, T. R. & Powers, J. H. Biomarkers and surrogate endpoints in clinical trials. Stat. Med. 31, 2973\u20132984 (2012).","journal-title":"Stat. Med."},{"key":"487_CR31","doi-asserted-by":"publisher","first-page":"101028","DOI":"10.1016\/j.patter.2024.101028","volume":"5","author":"K Zhang","year":"2024","unstructured":"Zhang, K. et al. Concepts and applications of digital twins in healthcare and medicine. Patterns 5, 101028 (2024).","journal-title":"Patterns"},{"key":"487_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-026-00427-5","author":"R Wu","year":"2026","unstructured":"Wu, R. et al. Digital twins and digital models of the human circulatory system. Nat. Rev. Bioeng. https:\/\/doi.org\/10.1038\/s44222-026-00427-5 (2026).","journal-title":"Nat. Rev. Bioeng."},{"key":"487_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"XP Duan","year":"2024","unstructured":"Duan, X. P. et al. New clinical trial design in precision medicine: discovery, development and direction. Signal. Transduct. Target. Ther. 9, 57 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"487_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-025-00592-0","volume":"11","author":"H Akbarialiabad","year":"2025","unstructured":"Akbarialiabad, H. et al. Enhancing randomized clinical trials with digital twins. npj Syst. Biol. Appl. 11, 110 (2025).","journal-title":"npj Syst. Biol. Appl."},{"key":"487_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41746-025-02048-5","volume":"8","author":"A Badani","year":"2025","unstructured":"Badani, A., de Moraes, F. Y., Vollmuth, P., Chung, C. & Mansouri, A. AI and innovation in clinical trials. npj Digit. Med. 8, 683 (2025).","journal-title":"npj Digit. Med."},{"key":"487_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53081-z","volume":"15","author":"Q Jin","year":"2024","unstructured":"Jin, Q. et al. Matching patients to clinical trials with large language models. Nat. Commun. 15, 9074 (2024).","journal-title":"Nat. Commun."},{"key":"487_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50996","volume":"6","author":"C Shadbolt","year":"2023","unstructured":"Shadbolt, C. et al. Analysis of rates of completion, delays, and participant recruitment in randomized clinical trials in surgery. JAMA Netw. Open 6, e2250996 (2023).","journal-title":"JAMA Netw. Open"},{"key":"487_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059230","volume":"12","author":"RM Jacques","year":"2022","unstructured":"Jacques, R. M. et al. Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the national institute for health research (NIHR) journals library (1997\u20132020). BMJ Open 12, e059230 (2022).","journal-title":"BMJ Open"},{"key":"487_CR39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/anae.15297","volume":"76","author":"JPA Ioannidis","year":"2021","unstructured":"Ioannidis, J. P. A. Hundreds of thousands of zombie randomised trials circulate among us. Anaesthesia 76, 444\u2013447 (2021).","journal-title":"Anaesthesia"},{"key":"487_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/anae.15263","volume":"76","author":"JB Carlisle","year":"2021","unstructured":"Carlisle, J. B. False individual patient data and zombie randomised controlled trials submitted to anaesthesia. Anaesthesia 76, 472\u2013479 (2021).","journal-title":"Anaesthesia"},{"key":"487_CR41","doi-asserted-by":"publisher","DOI":"10.1523\/eneuro.0470-25.2025","author":"C Bernard","year":"2026","unstructured":"Bernard, C. AI-generated scientific papers: crisis? What crisis? eNeuro https:\/\/doi.org\/10.1523\/eneuro.0470-25.2025 (2026).","journal-title":"eNeuro"},{"key":"487_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJM199103213241201","volume":"324","author":"DS Echt","year":"1991","unstructured":"Echt, D. S. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N. Engl. J. Med. 324, 781\u2013788 (1991).","journal-title":"N. Engl. J. Med."},{"key":"487_CR43","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109\u20132122 (2007).","journal-title":"N. Engl. J. Med."},{"key":"487_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"Yusuf, S., Pitt, B., Davis, C. E., Hood, W. B. & Cohn, J. N. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293\u2013302 (1991).","journal-title":"N. Engl. J. Med."},{"key":"487_CR45","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41591-020-1037-7","volume":"26","author":"S Cruz Rivera","year":"2020","unstructured":"Cruz Rivera, S., Liu, X., Chan, A. W., Denniston, A. K. & Calvert, M. J. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nat. Med. 26, 1351\u20131363 (2020).","journal-title":"Nat. Med."},{"key":"487_CR46","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s44222-024-00212-2","volume":"2","author":"J Goldhahn","year":"2024","unstructured":"Goldhahn, J., Brasier, N. & Kehoe, L. Digitalizing health trials by the clinical trials transformation initiative. Nat. Rev. Bioeng. 2, 717\u2013718 (2024).","journal-title":"Nat. Rev. Bioeng."},{"key":"487_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.2322","author":"O Aubert","year":"2019","unstructured":"Aubert, O. et al. Disparities in acceptance of deceased donor kidneys between the United States and France and estimated effects of increased US acceptance. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2019.2322 (2019).","journal-title":"JAMA Intern. Med."},{"key":"487_CR48","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","volume":"390","author":"A Levin","year":"2017","unstructured":"Levin, A. et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390, 1888\u20131917 (2017).","journal-title":"Lancet"},{"key":"487_CR49","doi-asserted-by":"publisher","first-page":"l4923","DOI":"10.1136\/bmj.l4923","volume":"366","author":"A Loupy","year":"2019","unstructured":"Loupy, A. et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. Br. Med. J. 366, l4923 (2019).","journal-title":"Br. Med. J."},{"key":"487_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052138","volume":"11","author":"O Aubert","year":"2021","unstructured":"Aubert, O. et al. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open 11, e052138 (2021).","journal-title":"BMJ Open"},{"key":"487_CR51","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ajt.2023.07.004","volume":"23","author":"J Hogan","year":"2023","unstructured":"Hogan, J. et al. Validation of a prediction system for risk of kidney allograft failure in pediatric kidney transplant recipients: an international observational study. Am. J. Transplant. 23, 1561\u20131569 (2023).","journal-title":"Am. J. Transplant."},{"key":"487_CR52","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s43856-022-00201-9","volume":"2","author":"G Divard","year":"2022","unstructured":"Divard, G. et al. Comparison of artificial intelligence and human-based prediction and stratification of the risk of long-term kidney allograft failure. Commun. Med. 2, 150 (2022).","journal-title":"Commun. Med."},{"key":"487_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.12.011","author":"A Truchot","year":"2022","unstructured":"Truchot, A. et al. Machine learning does not outperform traditional statistical modelling for kidney allograft failure prediction. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2022.12.011 (2022).","journal-title":"Kidney Int."},{"key":"487_CR54","doi-asserted-by":"publisher","DOI":"10.1681\/asn.0000000517","author":"A Truchot","year":"2024","unstructured":"Truchot, A. et al. Competing and noncompeting risk models for predicting kidney allograft failure. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/asn.0000000517 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"487_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18939","volume":"3","author":"X Paoletti","year":"2020","unstructured":"Paoletti, X. et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw. Open 3, e1918939 (2020).","journal-title":"JAMA Netw. Open"},{"key":"487_CR56","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/annonc\/mdw132","volume":"27","author":"S Michiels","year":"2016","unstructured":"Michiels, S. et al. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann. Oncol. 27, 1029\u20131034 (2016).","journal-title":"Ann. Oncol."},{"key":"487_CR57","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse, M. et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J. Clin. Oncol. 25, 5218\u20135224 (2007).","journal-title":"J. Clin. Oncol."},{"key":"487_CR58","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","volume":"36","author":"NI Cherny","year":"2025","unstructured":"Cherny, N. I. et al. ESMO \u2014 Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). Ann. Oncol. 36, 866\u2013908 (2025).","journal-title":"Ann. Oncol."},{"key":"487_CR59","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"GC Ebers","year":"1998","unstructured":"Ebers, G. C. & PRISMS (Prevention of Relapses and Disability by Interferon \u03b2-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis. Lancet 352, 1498\u20131504 (1998).","journal-title":"Lancet"},{"key":"487_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402\u2013415 (2010).","journal-title":"N. Engl. J. Med."},{"key":"487_CR61","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387\u2013401 (2010).","journal-title":"N. Engl. J. Med."},{"key":"487_CR62","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"487_CR63","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","volume":"12","author":"MP Sormani","year":"2013","unstructured":"Sormani, M. P. & Bruzzi, P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 12, 669\u2013676 (2013).","journal-title":"Lancet Neurol."},{"key":"487_CR64","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"A Scalfari","year":"2010","unstructured":"Scalfari, A. et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133, 1914\u20131929 (2010).","journal-title":"Brain"},{"key":"487_CR65","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jalz.2015.05.007","volume":"11","author":"MW Weiner","year":"2015","unstructured":"Weiner, M. W. & Veitch, D. P. Introduction to special issue: overview of Alzheimer\u2019s disease neuroimaging initiative. Alzheimers Dement. 11, 730\u2013733 (2015).","journal-title":"Alzheimers Dement."},{"key":"487_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70831","volume":"21","author":"L Du","year":"2025","unstructured":"Du, L. et al. Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms. Alzheimers Dement. 21, e70831 (2025).","journal-title":"Alzheimers Dement."},{"key":"487_CR67","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2017.18391","volume":"319","author":"AL Beam","year":"2018","unstructured":"Beam, A. L. & Kohane, I. S. Big data and machine learning in health care. J. Am. Med. Assoc. 319, 1317\u20131318 (2018).","journal-title":"J. Am. Med. Assoc."},{"key":"487_CR68","first-page":"101472","volume":"59","author":"GA Cruz-Suarez","year":"2026","unstructured":"Cruz-Suarez, G. A. et al. When evidence meets artificial intelligence. Lancet Reg. Health Am. 59, 101472 (2026).","journal-title":"Lancet Reg. Health Am."},{"key":"487_CR69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1109\/OJEMB.2023.3345733","volume":"5","author":"F Servin","year":"2024","unstructured":"Servin, F. et al. Simulation of image-guided microwave ablation therapy using a digital twin computational model. IEEE Open J. Eng. Med. Biol. 5, 107\u2013124 (2024).","journal-title":"IEEE Open J. Eng. Med. Biol."},{"key":"487_CR70","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41746-022-00694-7","volume":"5","author":"KP Venkatesh","year":"2022","unstructured":"Venkatesh, K. P., Raza, M. M. & Kvedar, J. C. Health digital twins as tools for precision medicine: considerations for computation, implementation, and regulation. npj Digit. Med. 5, 150 (2022).","journal-title":"npj Digit. Med."},{"key":"487_CR71","doi-asserted-by":"publisher","first-page":"107681","DOI":"10.1016\/j.cmpb.2023.107681","volume":"240","author":"A Procopio","year":"2023","unstructured":"Procopio, A. et al. Combined mechanistic modeling and machine-learning approaches in systems biology \u2014 a systematic literature review. Comput. Methods Prog. Biomed. 240, 107681 (2023).","journal-title":"Comput. Methods Prog. Biomed."},{"key":"487_CR72","volume":"11","author":"D Wang","year":"2025","unstructured":"Wang, D. et al. Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer\u2019s disease. Alzheimers Dement. 11, e70181 (2025).","journal-title":"Alzheimers Dement."},{"key":"487_CR73","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s43588-024-00732-2","volume":"4","author":"M Yin","year":"2024","unstructured":"Yin, M. et al. A scalable framework for learning the geometry-dependent solution operators of partial differential equations. Nat. Comput. Sci. 4, 928\u2013940 (2024).","journal-title":"Nat. Comput. Sci."},{"key":"487_CR74","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1161\/CIRCULATIONAHA.124.070526","volume":"151","author":"MC Waight","year":"2025","unstructured":"Waight, M. C. et al. Personalized heart digital twins detect substrate abnormalities in scar-dependent ventricular tachycardia. Circulation 151, 521\u2013533 (2025).","journal-title":"Circulation"},{"key":"487_CR75","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.124.013660","volume":"18","author":"MC Waight","year":"2025","unstructured":"Waight, M. C. et al. Heart digital twins predict features of invasive reentrant circuits and ablation lesions in scar-dependent ventricular tachycardia. Circ. Arrhythm. Electrophysiol. 18, e013660 (2025).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"487_CR76","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41551-019-0437-9","volume":"3","author":"PM Boyle","year":"2019","unstructured":"Boyle, P. M. et al. Computationally guided personalized targeted ablation of persistent atrial fibrillation. Nat. Biomed. Eng. 3, 870\u2013879 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"487_CR77","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41551-018-0282-2","volume":"2","author":"A Prakosa","year":"2018","unstructured":"Prakosa, A. et al. Personalized virtual-heart technology for guiding the ablation of infarct-related ventricular tachycardia. Nat. Biomed. Eng. 2, 732\u2013740 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"487_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.hrthm.2023.10.019","volume":"21","author":"NA Trayanova","year":"2024","unstructured":"Trayanova, N. A. & Prakosa, A. Up digital and personal: how heart digital twins can transform heart patient care. Heart Rhythm 21, 89\u201399 (2024).","journal-title":"Heart Rhythm"},{"key":"487_CR79","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1152\/physrev.00017.2023","volume":"104","author":"NA Trayanova","year":"2024","unstructured":"Trayanova, N. A., Lyon, A., Shade, J. & Heijman, J. Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation. Physiol. Rev. 104, 1265\u20131333 (2024).","journal-title":"Physiol. Rev."},{"key":"487_CR80","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.88865","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Predicting ventricular tachycardia circuits in patients with arrhythmogenic right ventricular cardiomyopathy using genotype-specific heart digital twins. eLife https:\/\/doi.org\/10.7554\/eLife.88865 (2023).","journal-title":"eLife"},{"key":"487_CR81","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s44222-023-00096-8","volume":"1","author":"AH Song","year":"2023","unstructured":"Song, A. H. et al. Artificial intelligence for digital and computational pathology. Nat. Rev. Bioeng. 1, 930\u2013949 (2023).","journal-title":"Nat. Rev. Bioeng."},{"key":"487_CR82","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0140-6736(12)61265-3","volume":"381","author":"C Lefaucheur","year":"2013","unstructured":"Lefaucheur, C. et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 381, 313\u2013319 (2013).","journal-title":"Lancet"},{"key":"487_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13113-5","volume":"10","author":"A Koenig","year":"2019","unstructured":"Koenig, A. et al. Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. Nat. Commun. 10, 5350 (2019).","journal-title":"Nat. Commun."},{"key":"487_CR84","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJMoa2408835","volume":"392","author":"M Sablik","year":"2025","unstructured":"Sablik, M. et al. Microvascular inflammation of kidney allografts and clinical outcomes. N. Engl. J. Med. 392, 763\u2013776 (2025).","journal-title":"N. Engl. J. Med."},{"key":"487_CR85","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","volume":"29","author":"F Eskandary","year":"2018","unstructured":"Eskandary, F. et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. J. Am. Soc. Nephrol. 29, 591\u2013605 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"487_CR86","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.ajt.2024.12.004","volume":"25","author":"Y Lombardi","year":"2025","unstructured":"Lombardi, Y. et al. Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system. Am. J. Transplant. 25, 1130\u20131132 (2025).","journal-title":"Am. J. Transplant."},{"key":"487_CR87","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa2400763","volume":"391","author":"KA Mayer","year":"2024","unstructured":"Mayer, K. A. et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N. Engl. J. Med. 391, 122\u2013132 (2024).","journal-title":"N. Engl. J. Med."},{"key":"487_CR88","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1097\/TP.0000000000003496","volume":"105","author":"SC Jordan","year":"2021","unstructured":"Jordan, S. C. et al. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes). Transplantation 105, 1808\u20131817 (2021).","journal-title":"Transplantation"},{"key":"487_CR89","doi-asserted-by":"publisher","first-page":"14343","DOI":"10.3389\/ti.2025.14343","volume":"38","author":"KA Mayer","year":"2025","unstructured":"Mayer, K. A., Budde, K., Diebold, M., Halloran, P. F. & B\u00f6hmig, G. A. Targeting CD38 in antibody-mediated rejection. Transpl. Int. 38, 14343 (2025).","journal-title":"Transpl. Int."},{"key":"487_CR90","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-05068-3","volume":"610","author":"F Andre","year":"2022","unstructured":"Andre, F. et al. Genomics to select treatment for patients with metastatic breast cancer. Nature 610, 343\u2013348 (2022).","journal-title":"Nature"},{"key":"487_CR91","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","volume":"15","author":"F Andr\u00e9","year":"2014","unstructured":"Andr\u00e9, F. et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01\/UNICANCER). Lancet Oncol. 15, 267\u2013274 (2014).","journal-title":"Lancet Oncol."},{"key":"487_CR92","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41591-022-01788-1","volume":"28","author":"O Mir","year":"2022","unstructured":"Mir, O. et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat. Med. 28, 1224\u20131231 (2022).","journal-title":"Nat. Med."},{"key":"487_CR93","doi-asserted-by":"publisher","first-page":"104734","DOI":"10.1016\/j.jbi.2024.104734","volume":"159","author":"M Rybinski","year":"2024","unstructured":"Rybinski, M., Kusa, W., Karimi, S. & Hanbury, A. Learning to match patients to clinical trials using large language models. J. Biomed. Inform. 159, 104734 (2024).","journal-title":"J. Biomed. Inform."},{"key":"487_CR94","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s44222-025-00279-5","volume":"3","author":"F Liu","year":"2025","unstructured":"Liu, F. et al. Application of large language models in medicine. Nat. Rev. Bioeng. 3, 445\u2013464 (2025).","journal-title":"Nat. Rev. Bioeng."},{"key":"487_CR95","doi-asserted-by":"publisher","DOI":"10.2196\/69485","volume":"13","author":"Z Yao","year":"2025","unstructured":"Yao, Z., Duan, L., Xu, S., Chi, L. & Sheng, D. Performance of large language models in the non-English context: qualitative study of models trained on different languages in chinese medical examinations. JMIR Med. Inform. 13, e69485 (2025).","journal-title":"JMIR Med. Inform."},{"key":"487_CR96","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25953","volume":"7","author":"SV Shah","year":"2024","unstructured":"Shah, S. V. Accuracy, consistency, and hallucination of large language models when analyzing unstructured clinical notes in electronic medical records. JAMA Netw. Open 7, e2425953 (2024).","journal-title":"JAMA Netw. Open"},{"key":"487_CR97","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ajt.2023.09.019","volume":"24","author":"A Klein","year":"2024","unstructured":"Klein, A., Toll, A., Stewart, D. & Fitzsimmons, W. E. Applying propensity methods to the United States transplant registry for external real-world evidence control arms for 5-year survival in the BENEFIT study. Am. J. Transplant. 24, 250\u2013259 (2024).","journal-title":"Am. J. Transplant."},{"key":"487_CR98","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u2013764 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"487_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-026-02517-5","author":"BG Collaco","year":"2026","unstructured":"Collaco, B. G. et al. The role of agentic artificial intelligence in healthcare: a scoping review. npj Digit. Med. https:\/\/doi.org\/10.1038\/s41746-026-02517-5 (2026).","journal-title":"npj Digit. Med."},{"key":"487_CR100","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/GIM.0b013e3180a6e9ef","volume":"9","author":"JM Gudgeon","year":"2007","unstructured":"Gudgeon, J. M., McClain, M. R., Palomaki, G. E. & Williams, M. S. Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing. Genet. Med. 9, 473\u2013478 (2007).","journal-title":"Genet. Med."},{"key":"487_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-074819","volume":"384","author":"GS Collins","year":"2024","unstructured":"Collins, G. S. et al. Evaluation of clinical prediction models (part 1): from development to external validation. Br. Med. J. 384, e074819 (2024).","journal-title":"Br. Med. J."},{"key":"487_CR102","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.landig.2025.100916","volume":"7","author":"B Van Calster","year":"2025","unstructured":"Van Calster, B. et al. Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance. Lancet Digit. Health 7, 100916 (2025).","journal-title":"Lancet Digit. Health"},{"key":"487_CR103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41591-024-03328-5","volume":"31","author":"S Johri","year":"2025","unstructured":"Johri, S. et al. An evaluation framework for clinical use of large language models in patient interaction tasks. Nat. Med. 31, 77\u201386 (2025).","journal-title":"Nat. Med."},{"key":"487_CR104","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41746-025-01544-y","volume":"8","author":"GE Weissman","year":"2025","unstructured":"Weissman, G. E., Mankowitz, T. & Kanter, G. P. Unregulated large language models produce medical device-like output. npj Digit. Med. 8, 148 (2025).","journal-title":"npj Digit. Med."},{"key":"487_CR105","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1681\/ASN.2018010009","volume":"29","author":"J Pascual","year":"2018","unstructured":"Pascual, J. et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J. Am. Soc. Nephrol. 29, 1979\u20131991 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"487_CR106","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/TP.0000000000000958","volume":"100","author":"B Sautenet","year":"2016","unstructured":"Sautenet, B. et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 100, 391\u2013399 (2016).","journal-title":"Transplantation"},{"key":"487_CR107","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2215\/CJN.0000000000000411","volume":"19","author":"G Divard","year":"2024","unstructured":"Divard, G. et al. Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 19, 628\u2013637 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"487_CR108","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124\u20131140 (2006).","journal-title":"N. Engl. J. Med."},{"key":"487_CR109","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1212\/WNL.0b013e3181ea15aa","volume":"75","author":"MP Sormani","year":"2010","unstructured":"Sormani, M. P. et al. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 75, 302\u2013309 (2010).","journal-title":"Neurology"},{"key":"487_CR110","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser, S. L. et al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med. 383, 546\u2013557 (2020).","journal-title":"N. Engl. J. Med."},{"key":"487_CR111","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMc2517822","volume":"394","author":"J Chrispin","year":"2026","unstructured":"Chrispin, J. et al. Digital twin-guided ablation for ventricular tachycardia. N. Engl. J. Med. 394, 1345\u20131347 (2026).","journal-title":"N. Engl. J. Med."},{"key":"487_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26297","volume":"10","author":"C Mennella","year":"2024","unstructured":"Mennella, C., Maniscalco, U., De Pietro, G. & Esposito, M. Ethical and regulatory challenges of AI technologies in healthcare: a narrative review. Heliyon 10, e26297 (2024).","journal-title":"Heliyon"},{"key":"487_CR113","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.ajt.2023.04.018","volume":"23","author":"A Klein","year":"2023","unstructured":"Klein, A. et al. Qualifying a novel clinical trial endpoint (iBOX) predictive of long-term kidney transplant outcomes. Am. J. Transplant. 23, 1496\u20131506 (2023).","journal-title":"Am. J. Transplant."},{"key":"487_CR114","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41591-020-1034-x","volume":"26","author":"X Liu","year":"2020","unstructured":"Liu, X., Cruz Rivera, S., Moher, D., Calvert, M. J. & Denniston, A. K. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat. Med. 26, 1364\u20131374 (2020).","journal-title":"Nat. Med."},{"key":"487_CR115","doi-asserted-by":"crossref","unstructured":"Liu, F., Wang, H., Cho, J., Roth, D. & Lo, A. AutoCT: automating interpretable clinical trial prediction with LLM agents. In Proc. 2025 Conference on Empirical Methods in Natural Language Processing (eds Christodoulopoulos, C. et al.) 30945\u201330970 (Association for Computational Linguistics, 2025).","DOI":"10.18653\/v1\/2025.emnlp-main.1575"},{"key":"487_CR116","doi-asserted-by":"publisher","unstructured":"Makarov, N. et al. TwinWeaver: an LLM-based foundation model framework for pan-cancer digital twins. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2601.20906 (2026).","DOI":"10.48550\/arXiv.2601.20906"},{"key":"487_CR117","doi-asserted-by":"publisher","unstructured":"Soykan, B., Koksalmis, G. H., Huang, H.-H. & Brattain, L. J. Cognitivetwin: robust multi-modal digital twins for predicting cognitive decline in Alzheimer\u2019s disease. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2604.22428 (2026).","DOI":"10.48550\/arXiv.2604.22428"},{"key":"487_CR118","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","volume":"31","author":"Z Xu","year":"2025","unstructured":"Xu, Z. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat. Med. 31, 2602\u20132610 (2025).","journal-title":"Nat. Med."},{"key":"487_CR119","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-024-03301-2","volume":"31","author":"H Pulaski","year":"2025","unstructured":"Pulaski, H. et al. Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis. Nat. Med. 31, 315\u2013322 (2025).","journal-title":"Nat. Med."},{"key":"487_CR120","doi-asserted-by":"publisher","first-page":"i263","DOI":"10.1093\/ecco-jcc\/jjae190.0137","volume":"19","author":"J Molnar","year":"2025","unstructured":"Molnar, J., McGuffog, J., Saralaya, R., Robas, N. & Phelan, A. DOP098 development of BEN8744, a phase 2 ready, peripherally restricted PDE10 inhibitor targeting a new mechanism of action for the treatment of ulcerative colitis. J. Crohns Colitis 19, i263 (2025).","journal-title":"J. Crohns Colitis"},{"key":"487_CR121","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30\u2013e31 (2020).","journal-title":"Lancet"},{"key":"487_CR122","doi-asserted-by":"publisher","first-page":"709856","DOI":"10.3389\/fphar.2021.709856","volume":"12","author":"DP Smith","year":"2021","unstructured":"Smith, D. P. et al. Expert-augmented computational drug repurposing identified baricitinib as a treatment for COVID-19. Front. Pharmacol. 12, 709856 (2021).","journal-title":"Front. Pharmacol."},{"key":"487_CR123","first-page":"2281","volume":"327","author":"R Rubin","year":"2022","unstructured":"Rubin, R. Baricitinib is first approved COVID-19 immunomodulatory treatment. J. Am. Med. Assoc. 327, 2281 (2022).","journal-title":"J. Am. Med. Assoc."},{"key":"487_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060951","author":"PJ Richardson","year":"2022","unstructured":"Richardson, P. J., Robinson, B. W. S., Smith, D. P. & Stebbing, J. The AI-assisted identification and clinical efficacy of baricitinib in the treatment of COVID-19. Vaccines https:\/\/doi.org\/10.3390\/vaccines10060951 (2022).","journal-title":"Vaccines"},{"key":"487_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13010148","author":"H Labinsky","year":"2023","unstructured":"Labinsky, H. et al. An AI-powered clinical decision support system to predict flares in rheumatoid arthritis: a pilot study. Diagnostics https:\/\/doi.org\/10.3390\/diagnostics13010148 (2023).","journal-title":"Diagnostics"},{"key":"487_CR126","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13075-021-02439-5","volume":"23","author":"A Vodencarevic","year":"2021","unstructured":"Vodencarevic, A. et al. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res. Ther. 23, 67 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"487_CR127","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/S2665-9913(21)00220-4","volume":"3","author":"K Tascilar","year":"2021","unstructured":"Tascilar, K. et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol. 3, e767\u2013e777 (2021).","journal-title":"Lancet Rheumatol."},{"key":"487_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06471-x","volume":"23","author":"MA Messelink","year":"2022","unstructured":"Messelink, M. A. et al. Prediction aided tapering in rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial. Trials 23, 494 (2022).","journal-title":"Trials"},{"key":"487_CR129","doi-asserted-by":"publisher","first-page":"CT114","DOI":"10.1158\/1538-7445.AM2023-CT114","volume":"83","author":"N Diaz","year":"2023","unstructured":"Diaz, N. et al. Abstract CT114: data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into phase 1 in RCC\/NSCLC. Cancer Res. 83, CT114 (2023).","journal-title":"Cancer Res."},{"key":"487_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49656-2","volume":"9","author":"CK Fisher","year":"2019","unstructured":"Fisher, C. K., Smith, A. M. & Walsh, J. R. Machine learning for comprehensive forecasting of Alzheimer\u2019s disease progression. Sci. Rep. 9, 13622 (2019).","journal-title":"Sci. Rep."},{"key":"487_CR131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41746-018-0040-6","volume":"1","author":"MD Abr\u00e0moff","year":"2018","unstructured":"Abr\u00e0moff, M. D., Lavin, P. T., Birch, M., Shah, N. & Folk, J. C. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. npj Digit. Med. 1, 39 (2018).","journal-title":"npj Digit. Med."},{"key":"487_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44676-z","volume":"15","author":"RM Wolf","year":"2024","unstructured":"Wolf, R. M. et al. Autonomous artificial intelligence increases screening and follow-up for diabetic retinopathy in youth: the ACCESS randomized control trial. Nat. Commun. 15, 421 (2024).","journal-title":"Nat. Commun."},{"key":"487_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-36970-9","volume":"16","author":"E Hunfeld","year":"2026","unstructured":"Hunfeld, E. et al. Real-world performance of the AI diagnostic system IDx-DR in the diagnosis of diabetic retinopathy and its main confounders. Sci. Rep. 16, 4349 (2026).","journal-title":"Sci. Rep."},{"key":"487_CR134","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1515\/ijb-2021-0072","volume":"18","author":"A Schuler","year":"2022","unstructured":"Schuler, A., Walsh, D., Hall, D., Walsh, J. & Fisher, C. Increasing the efficiency of randomized trial estimates via linear adjustment for a prognostic score. Int. J. Biostat. 18, 329\u2013356 (2022).","journal-title":"Int. J. Biostat."}],"container-title":["Nature Reviews Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00487-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:02:35Z","timestamp":1791547355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44222-026-00487-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":134,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1038\/s44222-026-00487-7","relation":{},"ISSN":["2731-6092"],"issn-type":[{"value":"2731-6092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"29 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M.D. has received recent Grants from NIH, DOD, and Cure Alzheimer Fund. P.M.D. is an advisor to Alzheon, Transposon, Keel Digital, Lumos, UMethod, Cornell, lululemon, and Prospira, and has served as an advisor to many other companies in the past. P.M.D. has received stock or options from Alzheon, UMethod, Evidation Health, Transposon and Marvel Biome. P.M.D. is a board member of AHEL Ltd and Live Love Laugh Foundation. P.M.D. has received gifts (through Duke) from Wrenn Trust, lululemon, Steve Aoki Foundation and Gates Ventures. P.M.D. is a co-inventor on diagnostic and therapeutic patents relating to dementia. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}